Chemical formula: C₁₈H₁₂ClF₃N₄O₄ Molecular mass: 440.76 g/mol PubChem compound: 487101
Delafloxacin inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II), enzymes required for bacterial DNA replication, transcription, repair, and recombination.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01MA23 | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| QUOFENIX Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| QUOFENIX Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| BAXDELA Tablet / Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Delafloxacin is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Ecuador (EC)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Italy (IT)
Lithuania (LT)
Poland (PL)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
